Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.56 |
| ▸ | LMNA | P02545 | 4/20 | 0.56 |
| ▸ | MIF | P14174 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 5/20 | 0.43 |
| ▸ | GAA | P10253 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | CTSD | P07339 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28263654 | 0.80 | SMN1; SMN2 (0.50) | ALDH1A1LMNAMIFMAPTGAA | |
| SCHEMBL1847472 | 0.78 | DAO (0.48) | ALDH1A1MIFMAPTMEN1KMT2A | |
| Hydrochloric Acid SCHEMBL8634171 | 0.77 | DAO (0.47) | ALDH1A1MIFMAPTMEN1KMT2A | |
| SCHEMBL8634167 | 0.77 | MIF (0.46) | ALDH1A1LMNAMIFMAPTMEN1 | |
| SCHEMBL2789975 | 0.77 | MAPT (0.48) | ALDH1A1LMNAMIFMAPTMEN1 | |
| SCHEMBL1844829 | 0.76 | MIF (0.43) | ALDH1A1LMNAMIFMAPTGAA | |
| SCHEMBL11213610 | 0.76 | KMT2A (0.49) | ALDH1A1LMNAMIFMAPTGAA | |
| Hydrochloric Acid SCHEMBL9780002 | 0.75 | SMN1; SMN2 (0.39) | ALDH1A1LMNAMIFMAPTGAA | |
| SCHEMBL18430372 | 0.72 | MIF (0.40) | ALDH1A1LMNAMIFMAPTMEN1 | |
| SCHEMBL18430395 | 0.72 | HDAC6 (0.49) | ALDH1A1MIFMAPTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6803379-B2 | TREATMENT OF VIRAL, BACTERIAL, PARASITIC, PROLIFERATIVE DISEASES, NEURODEGENERATIVE DISEASES, INFLAMMATORY DISEASES, HEAVY METAL POISONING AND IMMUNOGICAL DISEASES WITH THIOPHENE-2-CARBOXYLIC ACID, 2-FUROIC ACID OR DERIVATIVES | POL'S LABORATORIOS BIOTECHNOLOGY, S.A. (AR) | 2004-10-12 | — | — | US | disclosed |
| US-20040167204-A1 | Pharmacological agents and methods of treatment that inactivate pathogenic prokaryotic and eukaryotic cells and viruses by attacking highly conserved domains in structural metalloprotien and metalloenzyme targets | FERNANDEZ-POL JOSE A (US) | 2004-08-26 | — | — | US | disclosed |
| US-20030225155-A1 | Pharmacological agents and methods of treatment that inactivate pathogenic prokaryotic and eukaryotic cells and viruses by attacking highly conserved domains in structural metalloprotein and metalloenzyme targets | POL'S LABORATORIOS BIOTECHNOLOGY, S.A. (AR) | 2003-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040167204-A1 | Pharmacological agents and methods of treatment that inactivate pathogenic prokaryotic and eukaryotic cells and viruses by attacking highly conserved domains in structural metalloprotien and metalloenzyme targets | ZFX, ZFR, SLC30A6 | ALDH1A1 1453/4885LMNA 4716/4885MIF 152/4885 |
| US-20030225155-A1 | Pharmacological agents and methods of treatment that inactivate pathogenic prokaryotic and eukaryotic cells and viruses by attacking highly conserved domains in structural metalloprotein and metalloenzyme targets | ZFX, ZFR, SLC30A6 | ALDH1A1 1314/4885LMNA 4800/4885MIF 257/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.